Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2590443 in Acute Migraine Headache
NCT00804973Phase 2
Key facts
- Status
- Terminated
- Start
- Nov 2008
- Primary completion
- May 2009
- Countries
- 1
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Drugs
- LY2590443
- Conditions
- migraine
01
Overview
Phase 2, randomised, double-blind trial of LY2590443 in migraine (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Headache Pain Free Response at 2 hours. Started Nov 2008; status: terminated.
02
Design
3 arms- Study design
- RandomizedDouble-blind
LY2590443
200 mg oral LY2590443 + Placebo injection
Placebo
Placebo capsule + Placebo injection
Sumatriptan
6 mg Sumatriptan injection + Placebo capsule
03
Who it enrols
Adults 18-65 with a history of migraine for at least 1 year and 2-8 attacks per month, in good general health.
04
Endpoints
Primary
Number of Participants With Headache Pain Free Response
Secondary
Number of Participants With Pain Free Response
Number of Participants With Pain Relief Response
Number of Participants With Sustained Pain Relief Response
Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours
Number of Participants With Nausea
Number of Participants With Phonophobia
Number of Participants With Photophobia
Number of Participants With Vomiting
Beyond the preview
Go deeper on NCT00804973.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00804973.